Sponsors aim to move their products from development to commercialization as quickly and efficiently as possible. Traditionally, biotech, pharma, and MedTech companies have relied on the hope that the science will succeed and that a standard clinical research organization (CRO) model will get them to the finish line. However, with the evolving landscape, there's now a need for more personalization and agility—something that rigid CRO models typically don't offer.
ProPharma stands at the forefront of the clinical research organization industry, offering a comprehensive suite of services that span the entire drug, device and diagnostics development lifecycle. As a full-service CRO, ProPharma excels in providing end-to-end solutions, from early research to post-marketing surveillance. Our expertise encompasses Phase I-IV clinical research, regulatory sciences, pharmacovigilance, and quality assurance, ensuring that each project meets the highest standards of quality and compliance.
ProPharma’s innovative Research Consulting Organization (RCO) model further enhances our capabilities, offering a level of personalization and agility that traditional CRO models lack. The RCO model is designed to address the unique needs of small and midsize sponsors, particularly those focused on novel therapies and new medical devices. By combining strategic consulting with deep scientific and technical expertise, ProPharma provides bespoke solutions that are tailored to the specific requirements of each client. This approach not only optimizes the development process but also significantly increases the probability of success, making ProPharma the ideal partner for pharmaceutical and biotechnology & MedTech companies seeking top-tier CRO services.
When selecting a CRO, it is essential to consider several factors:
The CRO should have a proven track record in the therapeutic area relevant to the drug being developed. This includes expertise in handling complex development processes, particularly for biologics and cell and gene therapies.
Ensure the CRO adheres to high standards of quality and compliance with regulatory requirements such as Good Laboratory Practice (GLP) and Good Clinical Practice (GCP).
A top clinical research organization or CRO should offer a broad range of services that cover the entire drug development lifecycle, from early studies to post-marketing surveillance.
The ability to provide customized solutions that fit the unique needs of each project is crucial for ensuring optimal outcomes.
ProPharma’s client-focused approach ensures that every project benefits from our commitment to quality, innovation, and strategic consulting. Our dedication to improving patient health and safety drives their mission to deliver the technologies, medicines, and therapies of tomorrow.
ProPharma’s global reach and scalable solutions make us a reliable partner for both small startups and large pharmaceutical companies. By emphasizing strategic partnerships and bespoke solutions, ProPharma ensures that each client receives the support and expertise needed to navigate the complexities of drug and device development.
ProPharma is a global provider of patient-focused clinical research solutions to the pharmaceutical, biotechnology, and medical device and diagnostic industries. We are experts, with experience across all study phases and in a diverse and wide range of therapeutic areas. Our shared attributes of innovation, expertise, and passion are at the heart of everything we do.
Quick completion of Phase 1-2 trials to meet proof of concept goals is critical. We provide clinical expertise and an extended suite of early phase clinical development services specifically engineered to accelerate study progression.
Our integrated regulatory, pharmacology, statistics, and clinical experts design protocols that address and generate the data you need to make go and no-go decisions.
ProPharma offers a wide range of CRO services through our innovative and industry-defining RCO model, designed to support clients throughout the drug development process.
Comprehensive management of clinical trials, including site selection, patient recruitment, data management, and biostatistics.
Expertise in navigating the complex regulatory landscape, including preparing and submitting regulatory documents, ensuring compliance, and managing interactions with regulatory...
ProPharma's R&D Technology team offers a full range of strategic and technical consulting services, including technology road-mapping, digital blueprints, system integration,...
Implementing and maintaining robust quality management systems to ensure the highest standards of compliance and quality.
Monitoring and reporting adverse events, ensuring patient safety, and maintaining compliance with regulatory requirements.
Providing accurate and timely medical information to support healthcare professionals and patients.
ProPharma’s unique and revolutionary RCO model in combination with our comprehensive CRO service offerings and strategic approach enables pharmaceutical, biotechnology, medical device and diagnostics companies to bring new drugs and therapies to market efficiently and effectively.
As a full-service clinical research organization, ProPharma connects your clinical aspirations with our deep scientific and medical expertise, strong therapeutic insights, and unmatched clinical development experience to help you bring high-quality therapies to market fast – always with the patients’ safety in mind.
Our dedication to client success, quality, and innovation, we ensure that each project is tailored to meet specific needs, resulting in optimal outcomes and a higher probability of success.
October 18, 2018
Sponsors may transfer any or all of their many tasks and obligations relating to clinical trials to Contract Research Organizations (CROs). This ability to delegate through a Transfer of Regulatory...
October 19, 2017
Selecting the right contract research organization (CRO) is one of the most important decisions you, as a sponsor, must make. That’s because CROs can improve efficiency and increase productivity,...
May 25, 2021
The involvement of Medical Monitoring (MM) and Data Safety Monitoring Boards (DSMB) in trials has been somewhat unknown to individuals outside of clinical circles. That is, until media attention...
December 19, 2024
WHO issues guidance to control antibiotic pollution from manufacturing, addressing environmental and global health impacts of antimicrobial resistance.
December 18, 2024
Explore FDA's recommendations on follow-up testing for Ames-positive drugs to support first-in-human clinical trials. Learn how to navigate FDA regulations and ensuring successful product development.
December 17, 2024
Explore the importance of market access and reimbursement strategies for medical devices and in vitro diagnostics (IVDs) in Europe. Learn how early planning and the new European HTAR can enhance the...
October 21, 2024
ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.
October 9, 2024
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
September 30, 2024
Dawn Sherman rejoins ProPharma as CEO, bringing nearly 30 years of industry experience to lead the regulatory, clinical, and compliance services provider.
